Purpose: Inflammatory breast cancer (IBC) is the most aggressive type of breast cancer with a poor prognosis. Locoregional staging is based on dynamic contrast-enhanced (DCE) CT or MRI. The aim of this study was to compare the performances of FDG PET/CT and DCE CT in locoregional staging of IBC and to assess their respective prognostic values.
Methods: The study group comprised 50 women (median age: 51 ± 11 years) followed in our institution for IBC who underwent FDG PET/CT and DCE CT scans (median interval 5 ± 9 days). CT enhancement parameters were net maximal enhancement, net early enhancement and perfusion.
Results: The PET/CT scans showed intense FDG uptake in all primary tumours. Concordance rate between PET/CT and DCE CT for breast tumour localization was 92%. No significant correlation was found between SUVmax and CT enhancement parameters in primary tumours (p > 0.6). PET/CT and DCE CT results were poorly correlated for skin infiltration (kappa = 0.19). Ipsilateral foci of increased axillary FDG uptake were found in 47 patients (median SUV: 7.9 ± 5.4), whereas enlarged axillary lymph nodes were observed on DCE CT in 43 patients. Results for axillary node involvement were fairly well correlated (kappa = 0.55). Nineteen patients (38%) were found to be metastatic on PET/CT scan with a significant shorter progression-free survival than patients without distant lesions (p = 0.01). In the primary tumour, no statistically significant difference was observed between high and moderate tumour FDG uptake on survival, using an SUVmax cut-off of 5 (p = 0.7 and 0.9), or between high and low tumour enhancement on DCE CT (p > 0.8).
Conclusion: FDG PET/CT imaging provided additional information concerning locoregional involvement to that provided by DCE CT on and allowed detection of distant metastases in the same whole-body procedure. Tumour FDG uptake or CT enhancement parameters were not correlated and were not found to have any prognostic value.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00259-013-2405-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Is there a comparable Mp-MRI for incidental prostate uptake on 18 F-FDG PET/CT?
World J Surg Oncol
December 2024
Department of Urology, Başaksehir Çam and Sakura City Hospital, Istanbul, Turkey.
Purpose: Although 18 F-FDG-PET/CT is helpful in defining many types of cancer, localized prostate cancer should not be treated with this technique. This study describes the use of multi-parametric MRI (mpMRI) to characterize incidental 18 F-FDG uptake in the prostate.
Methods And Materials: While 18 F-FDG-PET/CT is useful for characterizing a variety of cancers, it is not advised for prostate cancer that is localized.
The Diagnostic Value of bpMRI in Prostate Cancer: Benefits and Limitations Compared to mpMRI.
Bioengineering (Basel)
October 2024
Department of Urology, 'Victor Babes' University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania.
Article Synopsis
- * Various diagnostic tools, including PSA tests, mpMRI, and the PI-RADS system, play critical roles in evaluating and managing prostate cancer, with mpMRI being the current standard for detailed imaging.
- * A study comparing bpMRI and mpMRI found that while bpMRI is reliable for assessing prostate volume and has benefits like lower cost and no contrast usage, mpMRI is superior for detecting more complex conditions and higher-risk lesions.
Value of Dynamic Contrast-Enhanced MRI for Grade Group Prediction in Prostate Cancer: A Radiomics Pilot Study.
Acad Radiol
August 2024
University Medical Imaging Toronto, Toronto Joint Department Medical Imaging, University Health Network, Sinai Health System, Women's College Hospital, University of Toronto, Toronto, Ontario, Canada.
Rationale And Objectives: To determine the role of dynamic contrast-enhanced (DCE) MRI-radiomics in predicting the International Society of Urological Pathology Grade Group (ISUP-GG) in therapy-naïve prostate cancer (PCa) patients.
Materials And Methods: In this ethics review board-approved retrospective study on two prospective clinical trials between 2017 and 2020, 73 men with suspected/confirmed PCa were included. All participants underwent multiparametric MRI.
ASL, DSC, DCE perfusion MRI and 18F-DOPA PET/CT in differentiating glioma recurrence from post-treatment changes.
Radiol Med
September 2024
NESMOS, Department of Neuroradiology, S. Andrea Hospital, University Sapienza, Via di Grottarossa 1035/1039, 00189, Rome, Italy.
Objectives: To discriminate between post-treatment changes and tumor recurrence in patients affected by glioma undergoing surgery and chemoradiation with a new enhancing lesion is challenging. We aimed to evaluate the role of ASL, DSC, DCE perfusion MRI, and 18F-DOPA PET/CT in distinguishing tumor recurrence from post-treatment changes in patients with glioma.
Materials And Methods: We prospectively enrolled patients with treated glioma (surgery plus chemoradiation) and a new enhancing lesion doubtful for recurrence or post-treatment changes.
Primary central nervous system post-transplantation lymphoproliferative disorder: A case report and systematic review of imaging findings.
Radiol Case Rep
June 2024
Department of Radiology, St. Josephs Hospital and Medical Center, Department of Pathology, 350 W Thomas Road, Phoenix, AZ 85013.
Primary central nervous system post-transplant lymphoproliferative disease (PCNS-PTLD) is a rare subset of post-transplant lymphoproliferative disorder (PTLD) isolated to the CNS without nodal or extra-nodal organ involvement [1,2]. PCNS-PTLD occurs primarily in patients following either solid organ transplants or hematopoietic stem cell transplants and tends to be monomorphic DLBCL. The development of PCNS-PTLD is commonly associated with EBV infection [3].
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!